| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6246882 | Transplantation Proceedings | 2016 | 4 Pages |
Abstract
IS therapy based on mTORi and low CNI dose ensures good graft survival, low rate of acute rejection, limited drug toxicity, and control of HIV disease. TARV has no significant interaction with IS therapy.
Related Topics
Health Sciences
Medicine and Dentistry
Surgery
Authors
A. Baisi, F. Nava, B. Baisi, E. Rubbiani, G. Guaraldi, F. Di Benedetto, M. Giovannoni, A. Solazzo, D. Bonucchi, G. Cappelli,